Amgen’s Lumakras: FDA Flags ‘Marginal’ Efficacy Results, Potential Systemic Bias In Lung Cancer Trial

Narrow passage
Do study conduct concerns tower over the narrow progression-free survival benefit for Lumakras? • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers